CN1822860B - 偶联生物分子及其制备 - Google Patents

偶联生物分子及其制备 Download PDF

Info

Publication number
CN1822860B
CN1822860B CN2004800198144A CN200480019814A CN1822860B CN 1822860 B CN1822860 B CN 1822860B CN 2004800198144 A CN2004800198144 A CN 2004800198144A CN 200480019814 A CN200480019814 A CN 200480019814A CN 1822860 B CN1822860 B CN 1822860B
Authority
CN
China
Prior art keywords
group
polymer
chemical compound
protein
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2004800198144A
Other languages
English (en)
Chinese (zh)
Other versions
CN1822860A (zh
Inventor
安东尼·罗伯特·戈德温
埃莉萨·佩多内
崔志元
苏尼尔·肖纳克
斯蒂芬·詹姆斯·布罗基尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abzena UK Ltd
Original Assignee
Polytherics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27742023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1822860(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Polytherics Ltd filed Critical Polytherics Ltd
Publication of CN1822860A publication Critical patent/CN1822860A/zh
Application granted granted Critical
Publication of CN1822860B publication Critical patent/CN1822860B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F10/00—Homopolymers and copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrrole Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2004800198144A 2003-07-11 2004-07-12 偶联生物分子及其制备 Expired - Lifetime CN1822860B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0316294.8A GB0316294D0 (en) 2003-07-11 2003-07-11 Conjugated biological molecules and their preparation
GB0316294.8 2003-07-11
PCT/GB2004/002994 WO2005007197A2 (en) 2003-07-11 2004-07-12 Conjugated biological molecules and their preparation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2010101399434A Division CN101792525B (zh) 2003-07-11 2004-07-12 偶联生物分子及其制备

Publications (2)

Publication Number Publication Date
CN1822860A CN1822860A (zh) 2006-08-23
CN1822860B true CN1822860B (zh) 2010-05-05

Family

ID=27742023

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2004800198144A Expired - Lifetime CN1822860B (zh) 2003-07-11 2004-07-12 偶联生物分子及其制备
CN2010101399434A Expired - Lifetime CN101792525B (zh) 2003-07-11 2004-07-12 偶联生物分子及其制备

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010101399434A Expired - Lifetime CN101792525B (zh) 2003-07-11 2004-07-12 偶联生物分子及其制备

Country Status (13)

Country Link
US (4) US7595292B2 (enExample)
EP (4) EP2133099B1 (enExample)
JP (2) JP4958549B2 (enExample)
KR (1) KR101152500B1 (enExample)
CN (2) CN1822860B (enExample)
AT (1) ATE440620T1 (enExample)
AU (2) AU2004257448B2 (enExample)
DE (1) DE602004022824D1 (enExample)
DK (4) DK1648518T3 (enExample)
ES (4) ES2549427T3 (enExample)
GB (1) GB0316294D0 (enExample)
PL (2) PL2253330T3 (enExample)
WO (1) WO2005007197A2 (enExample)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5207590B2 (ja) 2002-12-26 2013-06-12 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド 増強された生物学的能力を有するインターフェロン−βのポリマー結合体
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
US7046714B2 (en) * 2003-09-10 2006-05-16 Intel Corporation Method and apparatus for Raman ring resonator based laser/wavelength converter
ES2533695T3 (es) * 2004-03-02 2015-04-14 Seattle Genetics, Inc. Anticuerpos cargados parcialmente y métodos para su conjugación
KR20080068004A (ko) * 2005-08-15 2008-07-22 아라나 테라퓨틱스 리미티드 뉴 월드 영장류 구조형성영역을 가진 조작 항체
BRPI0707425A2 (pt) * 2006-02-01 2011-05-03 Arana Therapeutics Ltd construção de anticorpo de domìnio, molécula isolada de ácido nucleico, composição farmacêutica, e, métodos para detectar tnf-alfa humano em uma amostra, e para tratar um distúrbio
US20080139790A1 (en) * 2006-12-08 2008-06-12 Jennings Philip A Chimeric antibodies
WO2008098930A1 (en) * 2007-02-14 2008-08-21 Biocompatibes Uk Limited Derivatisation of biological molecules
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
US8658148B2 (en) 2007-06-22 2014-02-25 Genzyme Corporation Chemically modified dendrimers
TWI360535B (en) * 2007-08-30 2012-03-21 Univ Nat Sun Yat Sen Sulfur-containing compound, method of preparation
JP5933923B2 (ja) * 2007-10-09 2016-06-22 ポリテリクス リミテッド 新規な複合タンパク質及びペプチド
ES2466340T3 (es) * 2008-04-24 2014-06-10 Cantab Biopharmaceuticals Patents Limited Conjugados de Factor IX con semividas extendidas
RU2016108598A (ru) 2008-06-30 2018-11-23 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Функционализированные полипептиды
MX2011000009A (es) 2008-07-10 2011-08-15 Esbatech Alcon Biomed Res Unit Metodos y composiciones para la administracion mejorada de macromoleculas.
KR101763559B1 (ko) 2008-07-21 2017-08-14 폴리테릭스 리미티드 생물학적 분자의 컨쥬게이팅을 위한 신규한 시약 및 방법
GB0817978D0 (en) * 2008-10-01 2008-11-05 Imp Innovations Ltd Peptides
EA201170647A1 (ru) * 2008-11-04 2011-12-30 Янссен Фармацевтика Нв Пептиды-агонисты crhr2 и их использование
GB0912485D0 (en) * 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method
GB0922354D0 (en) 2009-12-21 2010-02-03 Polytherics Ltd Novel polymer conjugates
WO2010100430A1 (en) 2009-03-04 2010-09-10 Polytherics Limited Conjugated proteins and peptides
US10370245B2 (en) 2009-06-22 2019-08-06 Sanford-Burnham Medical Research Institute Methods and compositions using peptides and proteins with C-terminal elements
GB0916576D0 (en) 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
GB0916578D0 (en) 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
FI124016B (fi) * 2009-10-26 2014-01-31 Vapo Oy Menetelmä biomassakuivattimessa käytetyn kuivatusilman lämmittämiseksi välipiirinesteen avulla sekä vesi-glykoliseoksen tai sitä vastaavan jäätymättömän välipiirinesteen käyttö biomassakuivattimessa käytetyn kuivatusilman lämmittämiseksi
WO2011057027A2 (en) 2009-11-04 2011-05-12 Janssen Pharmaceutica Nv Method for treating heart failure with stresscopin-like peptides
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase
CA2837588A1 (en) 2011-05-31 2012-12-06 Airware, Inc. Re-calibration of ab ndir gas sensors
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
US20150086524A1 (en) 2012-04-16 2015-03-26 Cantab Biopharmaceuticals Patents Limited Optimised subcutaneous therapeutic agents
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
GB201210770D0 (en) 2012-06-18 2012-08-01 Polytherics Ltd Novel conjugation reagents
US9650331B2 (en) 2012-06-18 2017-05-16 Polytherics Limited Conjugation reagents
EP2861261A2 (en) * 2012-06-19 2015-04-22 Polytherics Limited Process for preparation of antibody conjugates and antibody conjugates
IN2015DN02349A (enExample) 2012-10-24 2015-08-28 Polytherics Ltd
NO2789793T3 (enExample) 2012-10-24 2018-01-27
CN104853781B (zh) 2012-11-30 2017-10-24 诺华股份有限公司 从含二硫化物的蛋白质制备缀合物的方法
CA2892863C (en) 2012-12-10 2022-03-15 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
US10226535B2 (en) 2012-12-10 2019-03-12 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
EP2931316B1 (en) 2012-12-12 2019-02-20 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
EP2968593B1 (en) 2013-03-15 2024-11-20 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
GB201308738D0 (en) * 2013-05-15 2013-06-26 Polytherics Ltd Novel polymer conjugates
MX373528B (es) 2013-08-26 2020-04-21 Regeneron Pharma Composiciones farmacéuticas que contienen diasterómeros macrólidos, métodos para su síntesis y usos terapéuticos.
KR20160055253A (ko) 2013-09-12 2016-05-17 할로자임, 아이엔씨 변형된 항-상피세포 성장인자 수용체 항체 및 이의 사용 방법
BR112015032713B1 (pt) 2013-09-17 2023-03-21 Obi Pharma, Inc Composto, composição farmacêutica, uso de uma quantidade terapeuticamente efetiva da composição farmacêutica, e uso do composto
BR112016007736B1 (pt) 2013-10-11 2022-09-27 Mersana Therapeutics, Inc Armação polimérica, e, composição farmacêutica
IL245009B (en) 2013-10-11 2022-08-01 Asana Biosciences Llc Protein-polymer-drug conjugates
EA201691075A1 (ru) * 2013-11-26 2016-09-30 Новартис Аг Способы оксимной конъюгации с кетон-модифицированными полипептидами
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
EP3145552B1 (en) 2014-05-23 2020-03-04 Novartis AG Methods for making conjugates from disulfide-containing proteins
HK1231367A1 (zh) 2014-06-02 2017-12-22 Regeneron Pharmaceuticals, Inc. 抗体药物偶联物、试剂和制备方法及其治疗用途
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
ES2885854T3 (es) 2014-10-14 2021-12-15 Polytherics Ltd Proceso para la conjugación de un péptido o proteína con un reactivo que comprende un grupo saliente que incluye una porción de PEG
CA2975810C (en) * 2015-02-05 2025-05-13 Ablynx Nv NANOBODY DIMERS LINKED VIA C-TERMINAL ENGINEERED CYSTEINS
SG11201707148PA (en) 2015-03-27 2017-10-30 Regeneron Pharma Maytansinoid derivatives, conjugates thereof, and methods of use
US10098960B2 (en) 2015-04-03 2018-10-16 Ucl Business Plc Polymer conjugate
US10509035B2 (en) 2015-08-07 2019-12-17 Gamamabs Pharma Sa Antibodies, antibody drug conjugates and methods of use
JP2018532990A (ja) 2015-09-04 2018-11-08 オービーアイ ファーマ，インコーポレイテッド グリカンアレイおよび使用の方法
US10975161B2 (en) 2016-01-12 2021-04-13 Crescendo Biologics Limited Molecules that bind prostate specific membrane antigen (PSMA)
GB201601136D0 (en) 2016-01-21 2016-03-09 Mörgelin Matthias And Abdillahi Suado M Novel polypeptides and medical uses thereof
CN108779127B (zh) 2016-01-25 2022-07-05 里珍纳龙药品有限公司 美登素类化合物衍生物、其偶联物和使用方法
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
KR20180121786A (ko) 2016-03-29 2018-11-08 오비아이 파머 인코퍼레이티드 항체, 제약 조성물 및 방법
WO2017178828A1 (en) 2016-04-14 2017-10-19 Polytherics Limited Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring
KR20250048399A (ko) 2016-04-22 2025-04-08 오비아이 파머 인코퍼레이티드 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에 의한 암 면역요법
GB201608936D0 (en) 2016-05-20 2016-07-06 Polytherics Ltd Novel conjugates and novel conjugating reagents
ES2965349T3 (es) 2016-06-06 2024-04-12 Abzena Uk Ltd Anticuerpos, usos de los mismos y conjugados de los mismos
US11642400B2 (en) 2016-07-27 2023-05-09 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
JP7121724B2 (ja) 2016-07-29 2022-08-18 オービーアイ ファーマ，インコーポレイテッド ヒト抗体、医薬組成物及び方法
GB201614162D0 (en) 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
GB201615725D0 (en) 2016-09-15 2016-11-02 Polytherics Ltd Novel cytotoxic agents and conjugates thereof
CA3044274A1 (en) 2016-11-21 2018-05-24 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
US10772971B2 (en) 2017-06-22 2020-09-15 Mersana Therpeutics, Inc. Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
GB201711068D0 (en) 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB201909298D0 (en) 2019-06-28 2019-08-14 Colzyx Ab Novel compositions and uses thereof
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
GB202016456D0 (en) 2020-10-16 2020-12-02 Colzyx Ab Novel bioactive peptide combinations and uses thereof
CN119836305A (zh) 2022-07-15 2025-04-15 费恩治疗有限公司 抗体-药物缀合物
CN115304524A (zh) * 2022-07-21 2022-11-08 湖南大学 一种β-酰基烯丙基甲基砜类化合物及其高效合成方法
TW202421207A (zh) 2022-09-30 2024-06-01 大陸商上海迪諾醫藥科技有限公司 苯并氮雜卓衍生物、含其的偶聯物及其應用
AU2023393382A1 (en) 2022-12-14 2025-06-19 Pheon Therapeutics Ltd Cytotoxic compounds
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1302209A (zh) * 1998-04-28 2001-07-04 应用研究系统Ars股份公司 多元醇干扰素β偶联物
US20010011115A1 (en) * 1998-03-12 2001-08-02 J. Milton Harris Poly (ethylene glycol) derivatives with proximal reactive groups

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US680343A (en) * 1899-04-15 1901-08-13 Johan Peter Moeller Glove.
US3828412A (en) * 1971-03-19 1974-08-13 Dunham Bush Inc Method of forming high integrity epoxy joint between aluminum tubes
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0298101A1 (en) 1987-01-15 1989-01-11 Celltech Limited Thiol-reactive cross-linking reagents
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ES2247656T3 (es) 1989-04-19 2006-03-01 Enzon, Inc. Un proceso para formar un polipeptido modificado que comprende un polipeptido y un oxido de polialquileno.
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
JP3693671B2 (ja) 1991-03-15 2005-09-07 アムゲン インコーポレーテッド ポリペプチドのｐｅｇ化
WO1994004193A1 (en) 1992-08-21 1994-03-03 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5786387A (en) * 1994-03-23 1998-07-28 Meiji Seika Kabushiki Kaisha Lipid double-chain derivative containing polyoxyethylene
US5877224A (en) 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
GB9713979D0 (en) 1997-07-03 1997-09-10 Univ Nottingham Method for attaching peg to macromolecules
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
AU4934299A (en) * 1999-07-15 2001-02-05 Kuhnil Pharm. Co., Ltd. Novel water soluble-cyclosporine conjugated compounds
WO2001017515A1 (en) 1999-09-03 2001-03-15 School Of Pharmacy, University Of London Degradable polymers
US6828412B1 (en) 1999-09-03 2004-12-07 School Of Pharmacy, University Of London Degradable polymers
US6803438B1 (en) 1999-09-08 2004-10-12 Polytherics Limited Uniform molecular weight polymers
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
GB0400264D0 (en) 2004-01-07 2004-02-11 Polytherics Ltd Complexes
WO2008098930A1 (en) 2007-02-14 2008-08-21 Biocompatibes Uk Limited Derivatisation of biological molecules
JP5933923B2 (ja) 2007-10-09 2016-06-22 ポリテリクス リミテッド 新規な複合タンパク質及びペプチド
KR101763559B1 (ko) 2008-07-21 2017-08-14 폴리테릭스 리미티드 생물학적 분자의 컨쥬게이팅을 위한 신규한 시약 및 방법
WO2010100430A1 (en) 2009-03-04 2010-09-10 Polytherics Limited Conjugated proteins and peptides
GB0912485D0 (en) 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method
US9650331B2 (en) 2012-06-18 2017-05-16 Polytherics Limited Conjugation reagents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010011115A1 (en) * 1998-03-12 2001-08-02 J. Milton Harris Poly (ethylene glycol) derivatives with proximal reactive groups
CN1302209A (zh) * 1998-04-28 2001-07-04 应用研究系统Ars股份公司 多元醇干扰素β偶联物

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BROCCHINI ET AL.Molecular yardsticks.Synthesis of extended equilibriumtransfer alkylating cross-link reagents and their useintheformation of macrocycles.JOURNAL OR THE AMERICAN CHEMICAL SOCIETY110 15.1988,110(15),Scheme I,Scheme II,化合物12-17,32.
BROCCHINI ET AL.Molecular yardsticks.Synthesis of extended equilibriumtransfer alkylating cross-link reagents and their useintheformation of macrocycles.JOURNAL OR THE AMERICAN CHEMICAL SOCIETY110 15.1988,110(15),Scheme I,Scheme II,化合物12-17,32. *
DEL ROSARIO R B ET AL.SULFHYDRYL SITE-SPECIFIC CROSS-LINKINGANDLABELING OF MONOCLONAL ANTIBODIESBYAFLUORESCENTEQUILIBRIUMTRANSFERALKYLATIONCROSS-LINKREAGENT.BIOCONJUGATE CHEMISTRY1 1.1990,1(1),图1，schemeI.
DEL ROSARIO R B ET AL.SULFHYDRYL SITE-SPECIFIC CROSS-LINKINGANDLABELING OF MONOCLONAL ANTIBODIESBYAFLUORESCENTEQUILIBRIUMTRANSFERALKYLATIONCROSS-LINKREAGENT.BIOCONJUGATE CHEMISTRY1 1.1990,1(1),图1,schemeI. *
LIBERATORE F A ET AL.SITE-DIRECTED CHEMICAL MODIFICATION ANDCROSS-LINKING OF A MONOCLONALANTIBODYUSINGEQUILIBRIUM TRANSFERALKYLATINGCROSS-LINKREAGENTS.BIOCONJUGATE CHEMISTRY1 1.1990,1(1),scheme II,化合物12-15,scheme III.
LIBERATORE F A ET AL.SITE-DIRECTED CHEMICAL MODIFICATION ANDCROSS-LINKING OF A MONOCLONALANTIBODYUSINGEQUILIBRIUM TRANSFERALKYLATINGCROSS-LINKREAGENTS.BIOCONJUGATE CHEMISTRY1 1.1990,1(1),scheme II,化合物12-15,scheme III. *
ROBERTS M J ET AL.Chemistry for peptide and protein PEGylation.ADVANCED DRUG DELIVERY REVIEWS,AMSTERDAM,NL54 4.2002,54(4),图1，图6，图14（2）.
ROBERTS M J ET AL.Chemistry for peptide and protein PEGylation.ADVANCED DRUG DELIVERY REVIEWS,AMSTERDAM,NL54 4.2002,54(4),图1,图6,图14(2). *
WILBUR D SCOTT ET AL."Monoclonal antibody Fab＇ fragment cross-linking using equilibrium transfer alkylation reagents. A strategyforsite-specific conjugation of diagnostic and therapeuticagentswith F(ab＇)2 -2 fragments".BIOCONJUGATE CHEMISTRY5 3.1994,5(3),图2，图1和第234页第3自然段.
WILBUR D SCOTT ET AL."Monoclonal antibody Fab'fragment cross-linking using equilibrium transfer alkylation reagents.A strategyforsite-specific conjugation of diagnostic and therapeuticagentswith F(ab')2-2 fragments".BIOCONJUGATE CHEMISTRY5 3.1994,5(3),图2，图1和第234页第3自然段. *

Also Published As

Publication number Publication date
JP2007527382A (ja) 2007-09-27
US20090298154A1 (en) 2009-12-03
CN101792525B (zh) 2012-06-06
AU2010257308A1 (en) 2011-01-13
US9439974B2 (en) 2016-09-13
ES2632515T3 (es) 2017-09-13
JP5349552B2 (ja) 2013-11-20
JP2012021003A (ja) 2012-02-02
DK2133099T3 (en) 2017-07-31
DE602004022824D1 (de) 2009-10-08
WO2005007197A3 (en) 2005-03-31
AU2004257448A1 (en) 2005-01-27
US20060210526A1 (en) 2006-09-21
KR101152500B1 (ko) 2012-07-05
EP2253330A2 (en) 2010-11-24
EP1648518B1 (en) 2009-08-26
EP2133099A2 (en) 2009-12-16
AU2010257308B2 (en) 2012-01-12
AU2004257448B2 (en) 2010-09-23
GB0316294D0 (en) 2003-08-13
KR20060054286A (ko) 2006-05-22
EP2133099B1 (en) 2017-04-19
ES2542531T3 (es) 2015-08-06
DK1648518T3 (da) 2009-11-09
US7595292B2 (en) 2009-09-29
EP2277550A1 (en) 2011-01-26
ES2331004T3 (es) 2009-12-18
CN101792525A (zh) 2010-08-04
PL2253330T3 (pl) 2016-01-29
US7939630B2 (en) 2011-05-10
DK2253330T3 (en) 2015-10-19
EP1648518A2 (en) 2006-04-26
US8816051B2 (en) 2014-08-26
US20110182855A1 (en) 2011-07-28
EP2133099A3 (en) 2010-03-10
EP2253330A3 (en) 2011-03-09
EP2253330B1 (en) 2015-08-19
WO2005007197A2 (en) 2005-01-27
DK2277550T3 (en) 2015-08-03
ES2549427T3 (es) 2015-10-28
PL1648518T3 (pl) 2010-02-26
US20140369960A1 (en) 2014-12-18
CN1822860A (zh) 2006-08-23
EP2277550B1 (en) 2015-04-29
ATE440620T1 (de) 2009-09-15
JP4958549B2 (ja) 2012-06-20

Similar Documents

Publication Publication Date Title
CN1822860B (zh) 偶联生物分子及其制备
CN102099058B (zh) 用于缀合生物分子的新试剂和方法
CN101820920B (zh) 新的缀合蛋白质和肽
JP6250654B2 (ja) 複合体化試薬
EP2403538A1 (en) Conjugated proteins and peptides
CN101580585A (zh) 组氨酸选择性水溶性聚合物衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20100505